The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Morepen Laboratories approves hiving off of medical devices business
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated
